Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 288

1.

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML).

Claudiani S, Metelli S, Kamvar R, Szydlo R, Khan A, Byrne J, Gallipoli P, Bulley SJ, Horne GA, Rothwell K, Copland M, Clark RE, Khorashad JS, Foroni L, Milojkovic D, Apperley JF.

Blood. 2019 Nov 13;134(Supplement_1):26. doi: 10.1182/blood-2019-131500.

PMID:
31724022
2.

Prolonged treatment free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations.

Claudiani S, Apperley JF, Khan A, Khorashad JS, Milojkovic D.

Haematologica. 2019 Sep 19. pii: haematol.2019.234179. doi: 10.3324/haematol.2019.234179. [Epub ahead of print]

3.

Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality.

Innes AJ, Woolley P, Szydlo RM, Lozano S, Fernando F, Bansal D, Palanicawandar R, Milojkovic D, May PC, Nadal-Melsio E, Yebra-Fernandez E, Olavarria E, Apperley JF, Pavlů J.

Leukemia. 2019 Sep 2. doi: 10.1038/s41375-019-0572-z. [Epub ahead of print] No abstract available.

PMID:
31477799
4.

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP; International CML Foundation Genomics Alliance.

Leukemia. 2019 Aug;33(8):1835-1850. doi: 10.1038/s41375-019-0512-y. Epub 2019 Jun 17. Review.

PMID:
31209280
5.

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.

Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, Byrne J, de Lavallade H, Osborne W, Robinson L, O'Brien SG, Read L, Foroni L, Copland M.

Lancet Haematol. 2019 Jul;6(7):e375-e383. doi: 10.1016/S2352-3026(19)30094-8. Epub 2019 Jun 12.

PMID:
31201085
6.

Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1.

Xu D, Claudiani S, Naresh K, Mucklow S, Neelakantan P, Yebra E, Apperley JF, Khorashad J, Milojkovic D.

Leuk Lymphoma. 2019 Jun 11:1-2. doi: 10.1080/10428194.2019.1622101. [Epub ahead of print] No abstract available.

PMID:
31184233
7.

Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3.

Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G.

Toxicol Rep. 2019 Apr 19;6:369-379. doi: 10.1016/j.toxrep.2019.04.006. eCollection 2019.

8.

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second generation tyrosine kinase inhibitors.

Nteliopoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydlo R, Alikian M, Foong HE, Nikolakopoulou Z, Loaiza S, Khorashad JS, Milojkovic D, Perrotti D, Gale RP, Foroni L, Apperley JF.

Haematologica. 2019 May 9. pii: haematol.2018.200220. doi: 10.3324/haematol.2018.200220. [Epub ahead of print]

9.

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia.

Claudiani S, Gatenby A, Szydlo R, Nesr G, Abulafia AS, Palanicawandar R, Nteliopoulos G, Khorashad J, Foroni L, Apperley JF, Milojkovic D.

Haematologica. 2019 Nov;104(11):2206-2214. doi: 10.3324/haematol.2018.214809. Epub 2019 Mar 28.

10.

Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival.

Galleu A, Milojkovic D, Deplano S, Szydlo R, Loaiza S, Wynn R, Marks DI, Richardson D, Orchard K, Kanfer E, Tholouli E, Saif M, Sivaprakasam P, Lawson S, Bloor A, Pagliuca A, Potter V, Mehra V, Snowden JA, Vora A, Kishore B, Hunter H, Apperley JF, Dazzi F.

Br J Haematol. 2019 Apr;185(1):89-92. doi: 10.1111/bjh.15749. Epub 2019 Jan 13.

11.

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review.

Cortes JE, Apperley JF, DeAngelo DJ, Deininger MW, Kota VK, Rousselot P, Gambacorti-Passerini C.

J Hematol Oncol. 2018 Dec 27;11(1):143. doi: 10.1186/s13045-018-0685-2. Review.

12.

The argument for using imatinib in CML.

Claudiani S, Apperley JF.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):161-167. doi: 10.1182/asheducation-2018.1.161. Review.

PMID:
30504305
13.

Back to the future: Treatment-free remission and pregnancy in chronic myeloid leukemia.

Abruzzese E, de Fabritiis P, Trawinska MM, Niscola P, Apperley JF, Mauro MJ.

Eur J Haematol. 2019 Feb;102(2):197-199. doi: 10.1111/ejh.13192. Epub 2018 Nov 29. No abstract available.

PMID:
30403419
14.

Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma.

Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G.

Br J Haematol. 2019 May;185(3):588-592. doi: 10.1111/bjh.15569. Epub 2018 Sep 26. No abstract available.

15.

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.

Ottmann O, Saglio G, Apperley JF, Arthur C, Bullorsky E, Charbonnier A, Dipersio JF, Kantarjian H, Khoury HJ, Kim DW, Healey D, Strauss L, Cortes JE.

Blood Cancer J. 2018 Sep 3;8(9):88. doi: 10.1038/s41408-018-0122-3. No abstract available.

16.

Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies.

Beckerson J, Szydlo RM, Hickson M, Mactier CE, Innes AJ, Gabriel IH, Palanicawandar R, Kanfer EJ, Macdonald DH, Milojkovic D, Rahemtulla A, Chaidos A, Karadimitris A, Olavarria E, Apperley JF, Pavlu J.

Clin Nutr. 2019 Apr;38(2):738-744. doi: 10.1016/j.clnu.2018.03.008. Epub 2018 Mar 28.

17.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM.

Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22.

18.

Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signaling.

Xin X, Ding Y, Yang Y, Fu X, Zhou J, McKee CM, Muschel RJ, Gale RP, Apperley JF, Xu D.

Blood Cancer J. 2018 Feb 26;8(2):24. doi: 10.1038/s41408-018-0063-x. No abstract available.

19.

Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease.

Khoder A, Alsuliman A, Basar R, Sobieski C, Kondo K, Alousi AM, Szydlo R, Muftuoglu M, Shaim H, Apperley JF, Gokdemir E, Cooper N, Mehta RS, Marin D, Champlin R, Shpall E, Rezvani K.

Front Immunol. 2018 Jan 12;8:1937. doi: 10.3389/fimmu.2017.01937. eCollection 2017.

20.

Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.

Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, Apperley JF, Pohlreich D, Browne PV, Kobbe G, Isaksson C, Lenhoff S, Scheid C, Touzeau C, Jantunen E, Anagnostopoulos A, Yakoub-Agha I, Tanase A, Schaap N, Wiktor-Jedrzejczak W, Krejci M, Schönland SO, Morris C, Garderet L, Kröger N.

Haematologica. 2018 Mar;103(3):514-521. doi: 10.3324/haematol.2017.181339. Epub 2017 Dec 7.

21.

Cost and quality issues in establishing hematopoietic cell transplant program in developing countries.

Hashmi SK, Srivastava A, Rasheed W, Adil S, Wu T, Jagasia M, Nassar A, Hwang WYK, Hamidieh AA, Greinix HT, Pasquini MC, Apperley JF, Aljurf M.

Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):167-172. doi: 10.1016/j.hemonc.2017.05.017. Epub 2017 Jul 14. Review.

22.

Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortality.

Innes AJ, Mullish BH, Fernando F, Adams G, Marchesi JR, Apperley JF, Brannigan E, Davies F, Pavlů J.

Bone Marrow Transplant. 2017 Oct;52(10):1452-1454. doi: 10.1038/bmt.2017.151. Epub 2017 Jul 17. No abstract available.

23.

Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation.

Pavlů J, Auner HW, Szydlo RM, Sevillano B, Palani R, O'Boyle F, Chaidos A, Jakob C, Kanfer E, MacDonald D, Milojkovic D, Rahemtulla A, Bradshaw A, Olavarria E, Apperley JF, Pello OM.

Bone Marrow Transplant. 2017 Dec;52(12):1599-1601. doi: 10.1038/bmt.2017.113. Epub 2017 Jun 26.

24.

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.

Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, Byrne JL, de Lavallade H, O'Brien SG, Coffey T, Foroni L, Copland M.

Lancet Haematol. 2017 Jul;4(7):e310-e316. doi: 10.1016/S2352-3026(17)30066-2. Epub 2017 May 26.

25.

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.

Claudiani S, Apperley JF, Gale RP, Clark R, Szydlo R, Deplano S, Palanicawandar R, Khorashad J, Foroni L, Milojkovic D.

Haematologica. 2017 Aug;102(8):e297-e299. doi: 10.3324/haematol.2017.168740. Epub 2017 May 11. No abstract available.

26.

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.

Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE.

Cancer. 2017 Aug 1;123(15):2875-2880. doi: 10.1002/cncr.30558. Epub 2017 Apr 7.

27.

Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.

Alikian M, Gale RP, Apperley JF, Foroni L.

Biomol Detect Quantif. 2017 Feb 14;11:4-20. doi: 10.1016/j.bdq.2017.01.001. eCollection 2017 Mar. Review.

28.

Monomeric, porous type II collagen scaffolds promote chondrogenic differentiation of human bone marrow mesenchymal stem cells in vitro.

Tamaddon M, Burrows M, Ferreira SA, Dazzi F, Apperley JF, Bradshaw A, Brand DD, Czernuszka J, Gentleman E.

Sci Rep. 2017 Mar 3;7:43519. doi: 10.1038/srep43519.

29.

Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors.

Boulianne B, Robinson ME, May PC, Castellano L, Blighe K, Thomas J, Reid A, Müschen M, Apperley JF, Stebbing J, Feldhahn N.

Cell Rep. 2017 Feb 14;18(7):1687-1698. doi: 10.1016/j.celrep.2017.01.057.

30.

BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation.

Pello OM, Innes AJ, Bradshaw A, Finn SA, Uddin S, Bray E, Olavarria E, Apperley JF, Pavlů J.

Eur J Haematol. 2017 Jun;98(6):632-634. doi: 10.1111/ejh.12848. Epub 2017 Mar 1.

31.

Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity.

Wahl S, Drong A, Lehne B, Loh M, Scott WR, Kunze S, Tsai PC, Ried JS, Zhang W, Yang Y, Tan S, Fiorito G, Franke L, Guarrera S, Kasela S, Kriebel J, Richmond RC, Adamo M, Afzal U, Ala-Korpela M, Albetti B, Ammerpohl O, Apperley JF, Beekman M, Bertazzi PA, Black SL, Blancher C, Bonder MJ, Brosch M, Carstensen-Kirberg M, de Craen AJ, de Lusignan S, Dehghan A, Elkalaawy M, Fischer K, Franco OH, Gaunt TR, Hampe J, Hashemi M, Isaacs A, Jenkinson A, Jha S, Kato N, Krogh V, Laffan M, Meisinger C, Meitinger T, Mok ZY, Motta V, Ng HK, Nikolakopoulou Z, Nteliopoulos G, Panico S, Pervjakova N, Prokisch H, Rathmann W, Roden M, Rota F, Rozario MA, Sandling JK, Schafmayer C, Schramm K, Siebert R, Slagboom PE, Soininen P, Stolk L, Strauch K, Tai ES, Tarantini L, Thorand B, Tigchelaar EF, Tumino R, Uitterlinden AG, van Duijn C, van Meurs JB, Vineis P, Wickremasinghe AR, Wijmenga C, Yang TP, Yuan W, Zhernakova A, Batterham RL, Smith GD, Deloukas P, Heijmans BT, Herder C, Hofman A, Lindgren CM, Milani L, van der Harst P, Peters A, Illig T, Relton CL, Waldenberger M, Järvelin MR, Bollati V, Soong R, Spector TD, Scott J, McCarthy MI, Elliott P, Bell JT, Matullo G, Gieger C, Kooner JS, Grallert H, Chambers JC.

Nature. 2017 Jan 5;541(7635):81-86. doi: 10.1038/nature20784. Epub 2016 Dec 21.

32.

C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early- and long-term mortality.

Patel A, Szydlo RM, Auner HW, Kanfer EJ, MacDonald DH, Milojkovic D, Altaf S, Innes A, Gabriel I, Rahemtulla A, Chaidos A, Karadimitris A, Olavarria E, Apperley JF, Pavlů J.

Br J Haematol. 2018 Mar;180(6):889-892. doi: 10.1111/bjh.14454. Epub 2016 Nov 29. No abstract available.

33.

Matched unrelated donor transplants-State of the art in the 21st century.

Altaf SY, Apperley JF, Olavarria E.

Semin Hematol. 2016 Oct;53(4):221-229. doi: 10.1053/j.seminhematol.2016.07.002. Epub 2016 Jul 25. Review.

34.

Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia.

Claudiani S, Apperley JF, Deplano S, Khorashad J, Foroni L, Palanicawandar R, Perry R, Milojkovic D.

Am J Hematol. 2016 Nov;91(11):E480-E481. doi: 10.1002/ajh.24495. Epub 2016 Sep 3. No abstract available.

35.

Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia.

Gerrard G, Foong HE, Mudge K, Alikian M, Apperley JF, Foroni L.

Leuk Res. 2016 Oct;49:47-50. doi: 10.1016/j.leukres.2016.08.007. Epub 2016 Aug 13.

PMID:
27552679
36.

Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines.

Daley GQ, Hyun I, Apperley JF, Barker RA, Benvenisty N, Bredenoord AL, Breuer CK, Caulfield T, Cedars MI, Frey-Vasconcells J, Heslop HE, Jin Y, Lee RT, McCabe C, Munsie M, Murry CE, Piantadosi S, Rao M, Rooke HM, Sipp D, Studer L, Sugarman J, Takahashi M, Zimmerman M, Kimmelman J.

Stem Cell Reports. 2016 Jun 14;6(6):787-797. doi: 10.1016/j.stemcr.2016.05.001. Epub 2016 May 12.

37.

Chronic myeloid leukemia: reminiscences and dreams.

Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ.

Haematologica. 2016 May;101(5):541-58. doi: 10.3324/haematol.2015.139337. Review.

38.

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Conti RM.

J Natl Cancer Inst. 2016 Mar 4;108(7). doi: 10.1093/jnci/djw003. Print 2016 Jul.

39.

CML and tyrosine kinase inhibition: the hope becomes reality.

Apperley JF.

Lancet Haematol. 2015 May;2(5):e176-7. doi: 10.1016/S2352-3026(15)00072-1. Epub 2015 Apr 20. No abstract available.

PMID:
26688089
40.

A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation.

Paul DS, Jones A, Sellar RS, Mayor NP, Feber A, Webster AP, Afonso N, Sergeant R, Szydlo RM, Apperley JF, Widschwendter M, Mackinnon S, Marsh SG, Madrigal JA, Rakyan VK, Peggs KS, Beck S.

Genome Med. 2015 Dec 15;7:128. doi: 10.1186/s13073-015-0246-z.

41.

Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting.

Lishner M, Avivi I, Apperley JF, Dierickx D, Evens AM, Fumagalli M, Nulman I, Oduncu FS, Peccatori FA, Robinson S, Van Calsteren K, Vandenbroucke T, Van den Heuvel F, Amant F.

J Clin Oncol. 2016 Feb 10;34(5):501-8. doi: 10.1200/JCO.2015.62.4445. Epub 2015 Nov 30.

42.

Polymorphism in TGFB1 is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donors.

Arrieta-Bolaños E, Mayor NP, Marsh SG, Madrigal JA, Apperley JF, Kirkland K, Mackinnon S, Marks DI, McQuaker G, Perry J, Potter MN, Russell NH, Thomson K, Shaw BE.

Haematologica. 2016 Mar;101(3):382-90. doi: 10.3324/haematol.2015.134999. Epub 2015 Nov 26.

43.

Allogeneic transplantation for CML in the TKI era: striking the right balance.

Innes AJ, Milojkovic D, Apperley JF.

Nat Rev Clin Oncol. 2016 Feb;13(2):79-91. doi: 10.1038/nrclinonc.2015.193. Epub 2015 Nov 17. Review.

44.

Transmission of CML or of t(9; 22) and BCR/ABL? They are not the same.

Gale RP, Apperley JF.

Bone Marrow Transplant. 2015 Dec;50(12):1582. doi: 10.1038/bmt.2015.199. Epub 2015 Sep 14. No abstract available.

PMID:
26367226
45.

The impact of dasatinib on pregnancy outcomes.

Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF.

Am J Hematol. 2015 Dec;90(12):1111-5. doi: 10.1002/ajh.24186. Epub 2015 Oct 12.

46.

Managing pregnancy in chronic myeloid leukaemia.

Palani R, Milojkovic D, Apperley JF.

Ann Hematol. 2015 Apr;94 Suppl 2:S167-76. doi: 10.1007/s00277-015-2317-z. Epub 2015 Mar 27. Review.

PMID:
25814083
47.

Thyroid function abnormalities associated with ponatinib therapy in patients with chronic myeloid leukemia.

Palani R, Apperley JF, Reid A, Foroni L, Deplano S, Milojkovic D.

Thyroid. 2015 Jun;25(6):706-7. doi: 10.1089/thy.2014.0514. Epub 2015 Apr 28. No abstract available.

PMID:
25778107
48.

Chronic myeloid leukaemia.

Apperley JF.

Lancet. 2015 Apr 11;385(9976):1447-59. doi: 10.1016/S0140-6736(13)62120-0. Epub 2014 Dec 5. Review.

PMID:
25484026
49.

Chronic myeloid leukemia-transplantation in the tyrosine kinase era.

Innes AJ, Apperley JF.

Hematol Oncol Clin North Am. 2014 Dec;28(6):1037-53. doi: 10.1016/j.hoc.2014.08.002. Epub 2014 Oct 5. Review.

PMID:
25459178
50.

A retrospective multi-centre study of the effects of allogeneic haematopoietic SCT on pulmonary function.

Dharmagunawardena R, Pearce RM, Thomas G, Kirkland K, Perry J, Apperley JF, Medd P, Wilson KM, Orchard K, Jackson G, Snowden JA, Cook G, Brown JS.

Bone Marrow Transplant. 2014 Nov;49(11):1442-3. doi: 10.1038/bmt.2014.154. Epub 2014 Jul 21. No abstract available.

PMID:
25046217

Supplemental Content

Loading ...
Support Center